SLNO

Soleno Therapeutics, Inc. Common Stock
Data: 2026-02-02
$42.27
Price
7.86%
Change
$90.3199
52W High
$37.95
52W Low

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Quick Stats
Feb 02, 2026

54.4

AI Score

HOLD

0.93

Volume Ratio

Feb 26, 2026

Next Earnings

13

+ve Days (30d)

17

-ve Days (30d)

SLNO Stock Summary

Last updated Feb 02, 2026

SLNO is currently trading at $42.27, positioned below its 200-day moving average of $65.28, suggesting bearish momentum. The stock has a 52-week range of $37.95 to $90.3199.

Technical Analysis: The 50-day moving average stands at $46.47, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 41.893, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.139, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates SLNO at 54.4/100 with a HOLD recommendation.

SLNO (Soleno Therapeutics, Inc. Common Stock) Indicators

Last updated Feb 02, 2026

Indicator Value
RSI(14) 41.893
CMF (20) -0.139
ROC (10) -2.095
ADX (14) 14.053
Indicator Value
MACD (12,26,9) -1.828
AROONOSC (14) -92.857
WILLAMS %R (14) -44.427
MFI (14) 47.666
SLNO Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

SLNO Price vs Max Options Open Interest
SLNO Max Change In Options Open Interest

SLNO Options - Sort by Max open Interest (near term)

2nd February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

SLNO Daily Out of Money Options - Sort by Max open Interest (near term)

2nd February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

SLNO Daily In the Money Options - Sort by Max open Interest (near term)

2nd February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

SLNO Most Active Options by Volume(near term)

2nd February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Soleno Therapeutics, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

SLNO Moving Averages Analysis

SLNO (Soleno Therapeutics, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated Feb 02, 2026

Days MA
10 42.17
20 42.79
30 44.5
50 46.47
100 52.9
200 65.28

SLNO Fundamental Analysis

P/E (Forward) 7.9051
P/E (Trailing) --
Market Cap ($) 2.1 billion
Earnings/Share ($) -1.75
Net Proft Margin (%) -0.795
Dividend/Share ($) --
EPS Estimate Current Year ($) 0.2883
EPS Estimate Next Year ($) 4.3025
WallStreet Target Price ($) 111.9231
Most Recent Quarter